© GEORGE RETSECK
TAMPING DOWN TREGS
Tumors (purple cells) recruit abnormally high numbers of potently immune-suppressing Tregs, which repress effector T cells (1) and prevent cancer destruction. Addition of anti-TNFR2 monoclonal antibodies (2) targets and kills TNFR2-expressing Tregs, thereby boosting the activity of effector T cells, which attack the tumor (3). The antibodies can also directly kill tumor cells that express the TNFR2 receptor.
Read the full story.
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?